All of our sources are compiled in one place. Peer-reviewed academic papers appear at the top, then clinical trial registries, and finally pages from companies and official agencies. Blogs, forums, and vendor sites are left out.
Peer-reviewed publications
Jastreboff et al., NEJM 2023Phase 2, obesity, 48-week results Rosenstock et al., Lancet 2023Phase 2, type 2 diabetes, 36-week results Sanyal et al., Nature Medicine 2024Phase 2 substudy, liver fat
Trial registries
NCT05929066, TRIUMPH-1Phase 3, obesity / overweight NCT05929079, TRIUMPH-2Phase 3, obesity with type 2 diabetes NCT06383390Phase 3, TRIUMPH program
Company announcements
Eli Lilly, Phase 2 announcement2023 Eli Lilly, TRIUMPH-2 and -3 toplineJuly 2026, BLA planned Q1 2027
Regulators and public health
FDA MedWatchAdverse event reporting FDA, compounding lawsSections 503A / 503B NIDDKBackground on obesity medications
Links going off-site lead to third-party websites we don't oversee. Their inclusion should not be read as approval, and those organizations are not affiliated with our store in any way.
